Advertisement
Australia markets open in 5 hours 26 minutes
  • ALL ORDS

    7,994.20
    -82.50 (-1.02%)
     
  • AUD/USD

    0.6615
    +0.0033 (+0.50%)
     
  • ASX 200

    7,721.60
    -82.90 (-1.06%)
     
  • OIL

    79.08
    +0.09 (+0.11%)
     
  • GOLD

    2,341.00
    +18.70 (+0.81%)
     
  • Bitcoin AUD

    93,935.45
    -787.92 (-0.83%)
     
  • CMC Crypto 200

    1,338.31
    +38.21 (+2.94%)
     

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

HAYWARD, Calif., April 24, 2024--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

ADVERTISEMENT

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424694046/en/

Contacts

Investor Contacts:
Pulse Biosciences
Kevin Danahy, President and CEO
510.241.1077
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com